Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Recurrent/Metastatic Salivary Gland Carcinomas
NCT01703455Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in salivary gland carcinoma (SGC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Sep 2010; status: completed.
02
Drugs
sorafenib
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT01703455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703455.